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ABSTRACT 
Low back pain (LBP) is a significant burden with a lifetime prevalence of 84% 
and estimated expenditures of $85.9 billion.1,2 Although LBP is multifactorial; it has been 
shown that LBP can originate from degenerating intervertebral discs (IVDs); a process 
which initiates in the nucleus pulposus (NP); a hydrated tissue primarily composed of 
type 2 collagen and proteoglycan. Current therapies for IVD degeneration (IDD) are 
palliative and merely delay surgical management. While these procedures may relieve 
pain temporarily, they fail to address the underlying cause of degeneration and make no 
attempt to regenerate the effected tissue. Additional concerns with the use of these 
treatments include the potential for accelerating degeneration in adjacent IVDs and that 
they are surgical strategies typically employed only during the late stages of IDD 
progression.3–5  
The purpose of this research was to develop a decellularization procedure to 
create a biomimetic NP scaffold for use in the early-stages of IDD, which may assist in 
mitigating, halting or reversing the progression of degeneration. The objectives of this 
research were to: (1) develop a procedure to decellularize healthy bovine caudal NPs to 
eliminate xenogeneic cellular remnants while retaining type 2 collagen and 
glycosaminoglycan content, (2) evaluate the resultant scaffolds mechanical properties, 
and (3) evaluate the cytocompatiblity of the scaffold with human amniotic membrane 
derived mesenchymal stem cells (hAMSCs). 
Results illustrate our ability to remove greater than 93% of bovine DNA (with no 
residual base-pairs present). Concomitantly, greater than 200µg of glycosaminoglycan 
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(GAG) per milligram of sample dry weight was maintained. Furthermore measurement of 
hydroxyproline (HYP) content within NP scaffolds demonstrated a GAG:HYP ratio of 
15:1, which is comparable to values reported for healthy human NP6. Histological and 
macroscopic evaluations of the scaffold illustrate a GAG-rich matrix, which closely 
resembles the human NP and no presence of cells within the scaffold, thus the scaffold 
was referred to as an acellular bovine NP (ABNP) scaffold. Mechanical evaluations of 
this ABNP scaffold yielded viscoelastic properties similar to a healthy human native 
NP.7–9 Lastly, evaluation of the cytocompatibility has been performed and has proven the 
ability of the ABNP scaffold to maintain cell viability at 95% up to fourteen days. The 
results of this research indicate a promising scaffold for further analysis for the treatment 
of IDD. 
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CHAPTER ONE 
LITERATURE REVIEW 
1.1 The Clinical Significance of Intervertebral Disc Degeneration 
Low back pain (LBP) is a significant burden with a lifetime prevalence of 84% 
and estimated expenditures of $85.9 billion.1,2 Although LBP is multifactorial; it has been 
shown that LBP can originate from degenerating intervertebral discs (IVDs); a process 
which initiates in the nucleus pulposus (NP); a hydrated tissue primarily composed of 
type 2 collagen and the proteoglycan aggrecan. Current therapies for IVD degeneration 
(IDD) are palliative and merely delay surgical management. While these procedures may 
relieve pain temporarily, they fail to address the underlying cause of degeneration and 
make no attempt to regenerate the effected tissue. Additional concerns with the use of 
existing treatments, spinal fusion and total disc arthroplasty, include the potential for 
accelerating degeneration in adjacent IVDs and that they are surgical strategies typically 
employed only during the late stages of IDD progression.3–5  
1.2 The Gross Structure of the Nucleus Pulposus 
1.2.1 Biochemical Components of the Nucleus Pulposus 
The organization and composition of the NP is what defines its ability to perform 
in its specific physiological environment. A combination of collagen, proteoglycans, 
cells, MMPs, ADAMTS, & TIMPs combine in specific ratios not seen anywhere else in 
the body except in this specific environment. When the ratio of proteoglycans to collagen 
starts to fall and the cells begin to die the environment of the NP begins to change and 
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degrade in one of the most vicious cycles of degradation observed in the body. Without 
all of the components working synergistically the entire IVD will fail starting within the 
NP. In these situations the mechanical properties of the IVD degrade and are unable to 
support spinal loads. The major biochemical components of the NP are as follows: 
collagen, proteogycans, namely aggrecan, cells, and products of cells. These major 
components of the NP are responsible for defining the nature of the environment and all 
aid in supporting the mechanical loads demanded of the body. 
1.2.1.1 Proteoglycans 
Aggrecan is the largest component of the NP by dry weight, comprising 
approximately 50% of the tissue.5,10 Aggrecan is a proteoglycan known for its ability to 
retain water, which is necessary in the dynamic compression cycles the NP undergoes 
daily. It is comprised of a core protein backbone with link proteins that enable 
attatchment of aggrecan to a hylaronic acid backbone. Chondroiton sulfate (CS) and 
keratin sulfate (KS) (Figure 1.1) are also attached to the aggrecan protein giving the 
molecule its characteristic “bottle brush” architecture and fixed charge density. 
Furthermore aggrecan is comprised of three globular regions termed G1, G2, and G3, 
with a short interglobular domain (IGD) which separates G1 from G2, and a long GAG-
attachment region separating G2 from G3.11 The G1 region is responsible for interacting 
with the HA, connecting the two backbones together. The region between G2 and G3 can 
be split up into three regions known as KS, CS1, and CS2 where the GAGs are rich 
giving aggrecan its aggregating properties.11 Due to the numerous GAG chains aggrecan 
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provides the NP with osmotic properties that allow the structure swell and withstand 
compression. Specific to the NP the GAG to hydroxyproline (HYP) ratio is 27:1 whereas 
elsewhere cartilage throughout the body is closer to a 2:1 ratio.6,12 Also, due to this high 
concentration of aggrecan it has been shown that is also functions to impede angiogenesis 
and neurogenesis inside the NP.11,13,14 As aggrecan degenerates from use and age the 
onset of IDD begins. Aggrecan is cleaved at two notable regions causing the aggregates 
to be free floating and unable to retain water properly under compressive loads. These 
two sites for aggrecanases to cleave are the IGD and CS2 regions.11,15 The main 
aggrecanases, that will be discussed later, are MMP-3, 7, and 12 and ADAMTS-1, 4, 5, 8, 
and 15.11,15–17 These aggrecanases are found naturally in the NP tissue and are thought to 
be part of the normal tissue tunrnover for aggrecan however with age and other factors 
the rate of catabolism is much faster than the rate of anabolism of aggrecan therefore 
degeneration and breakdown of aggrecan occurs. This shift in aggrecan to collagen ratio 
begins a vicious cycle of breakdown and inflammation of NP tissue. Other proteoglycans 
present in the NP tissue are decorin, biglycan, fibimodulin and lumican, however their 
role is till unknown and remains to be a minor factor compared to aggrecan’s role in the 
NP.18 Aggrecan is a critical component for any attempts for tissue regeneration of the NP. 
This is because it is understandably difficult in order to artificially create aggrecan, 
therefore aggrecan either needs to be maintained in scaffold creation via a 
decellularization procedure or produced in large quantities by healthy NP-like cells. 
Therefore, any development of NP tissue replacements there is a critical need to provide 
large quantities of relative GAG content to not only condition any stem cells seeded on 
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the scaffold but to also maintain the critical biochemical and biomechanical properties 
needed for a functional NP replacement. 
Figure 1.1 Domain structure of aggrecan.11 
1.2.1.2 Collagen 
Collagen, primarily collagen type II, forms about 20-25%, or ~15µg HYP/mg 
tissue dry weight, of the NP dry weight tissue.5,10 Collagen type II forms a loose network 
with other collagens, type IX and XI, found within the NP to form cross-bridges between 
collagen type II molecules and other ECM components. Together they form a ECM 
matrix specialized in providing resistance to swelling (Figure 1.2).19,20  
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Figure 1.2: Depiction of the function of proteoglycans and collagen fibers within the NP21 
1.2.1.3 Cells 
Two different populations of cells are found to inhabit the NP. First are 
chondrocyte-like cells, known as NP cells, which have an approximate density of 4x106 
cells/cm3. These cells reside within lacunae and appear oval or rounded in shape.22,23 
These cells are responsible for producing all the ECM components and degradative 
enzymes and maintaining the GAG: HYP.  The second population of cells present within 
the NP is known as notochordal cells, which are highly vacuolated and populate the NP at 
birth but disappear by the age of 4-10 years in humans.24,25 The purpose of these is still 
unclear at this time.  
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1.2.2 Mechanical Properties of the Nucleus Pulposus 
The mechanical properties of the human NP are the definition of its biochemical 
properties. The properties of the human NP have been reported using a multitude of 
different types of mechanical testing, such as unconfined and confined compression using 
incremental strains for stress relaxation analysis.9,26 Data from unconfined compression 
defines the equilibrium modulus as 5.39 ±2.56 kPa, a Poisson’s ratio of 0.62 ± 0.15 at 
high strains and a Poisson’s ratio of 0.125 at low strains, and a percent relaxation of 
65.77 ± 11.3%.8,26 Utilizing confined compression it is possible to calculate the aggregate 
modulus, stiffness at zero flow, and permeability, resistance to fluid flow. The values of 
these of healthy human NP are 1.01 ± 0.43MPa and 0.9 ± 0.43 10-15 m4/N-s.27 Under 
dynamic testing conditions the NP behaves similarly to a solid since the storage modulus 
is always greater than the loss modulus no matter what frequency is tested. The phase 
angle (δ, the lag between stress and stain) of the human NP ranges from 15-27˚ over a 
testing frequency of 0.01-2 Hz indicating a viscoelastic response.9 The complex shear 
modulus, G*, ranges for the human NP between 7-21kPa.7 
1.3 Intervertebral Disc Degeneration 
IVD degeneration (IDD) is a cell-mediated process driven by several factors 
including genetics, injury, mechanical forces, and disc nutrition. The combination of the 
factors culminates in destructive changes to the NPs ECM. There is ultimately an 
imbalance of tissue production and destruction causing the natural ECM within the disc 
to change, therefore changing the mechanical properties of the NP. These structural 
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changes to the NP have four different grades ranging from mild degeneration to severe 
(Figure 1.3). 
Figure 1.3 Depiction of the different grades of IDD28 
1.3.1 Changes within the NP 
The overall changes being observed in degeneration of the NP s the imbalance of 
ECM turnover, matrix anabolism is not keeping pace with matrix catabolism.29 
Additionally, the production of proteases such as, matrix metalloproteinases (MMPs) and 
a disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs) without the 
production of tissue inhibitor of metalloproteinases (TIMPs) will cause an imbalance of 
matrix production. During this degeneration aggrecan and water content both decrease as 
well as the production of new proteoglycans decrease. This alteration further adds to the 
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degeneration of the NP. Increased fragmentation of aggrecan ultimately leads to reduced 
osmotic pressure within the NP causing a destabilization.11  
Cells are viewed as the primary reason for this degeneration for the NP due to 
their increased production of MMPs.29 These MMPs lead to the destruction and cleavage 
of aggrecan within the NP causing more significant changes to the structure of the NP. 
Without high amounts of intact aggrecan present within the NP it has been demonstrated 
that blood vessels and neural ingrowth can occur further destabilizing the NP as well as 
causing increased pain.13,14  
Due to biochemical changes in the NP the mechanical properties also change. The 
NP is unable to maintain the loading it was once capable of due to the loss of the osmotic 
pressure created by aggrecan. With the degeneration of the NP there a significantly 
increased shear modulus and effective aggregate modulus.4,27 These altered properties in 
turn cause a lost of disc height which in turn can pinch nerves in the spinal column 
further increasing pain. 
1.4  Current Treatments for IDD and Nucleus Pulposus Replacement 
Current surgical options are palliative and only treat the symptoms and not the 
cause of IDD. Additionally, surgical means affect the adjacent IVDs by changing the 
mechanics of the spinal functional unit further aiding to IDD. Present surgical options, 
total disc arthroplasty and spinal fusion, have been proven to help aid in relieving pain in 
the patient for a time but it is also known that the adjacent discs begin the process of 
degeneration due to the altered biomechanics in the region. The adjacent discs experience 
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greater pressure and are unable to move as freely as they were pre-surgical intervention 
and may require a second surgery to fix and eliminate pain again.30–36 Therefore it is 
imperative to find a treatment that attempts to mitigate or halt the progression of IDD in 
order to preserve the surrounding IVDs. 
 
1.5 Current Tissue Engineering Approaches to IDD 
1.5.1 Stem Cell Models 
For most tissue engineering approaches there a suitable cell source is critical and 
must be identified. A cell source is typically needed because there are dramatic 
reductions in viable cell numbers within degenerated tissue and the remaining cells may 
exhibit increased senescence and altered phenotype, this includes cells native to the NP.37 
Additionally, autologous NP cells are not a viable option for several factors: 1) NP cells 
are sparse and would therefore not provide adequate quantity for a primary cell culture, 
2) harvesting NP cells from adjacent healthy discs would cause degeneration from the 
IVDs harvested, 3) harvesting cells from the degenerated disc would only accelerate 
degeneration, 4) NP cells from degenerated disc, as discussed prior, exhibit altered 
phenotype, increased senescence, increased expression of degradative enzymes as well as 
limited capacity for matrix production.37–39 Therefore there is a need to find an alternative 
source of cells for regenerating the NP. 
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1.5.2 Utilization of Scaffolds 
The utilization of biomaterials has been heavily researched as an alternative 
treatment for IDD. While it has been shown that there are many stem cell sources may 
have a positive effect in treating IDD. It is evident that there needs to be a suitable 
scaffold material capable of supporting the survival of the stem cells. The environment of 
a degenerated disc is rich in degradative enzymes and proteases, which could cause issues 
for an implanted material.40,41 Therefore it may be beneficial to remove the degraded 
portions of the NP. This however, creates a void where a biomaterial will fill providing 
restorative factors to the NP. The scaffolds would therefore need to provide not only 
restorative factors but also provide mechanical support.  An ideal scaffold would protect 
cells, support differentiation of cell sources into NP-like cells, provide mechanical 
support, and degrade into non-cytotoxic components. To date, scaffolds developed are 
unable to closely mimic the biochemical or mechanical properties of the healthy human 
NP.42–45  
 
1.5.2.1 Natural Scaffolds for NP Regeneration 
The use of natural biomaterials for tissue engineering purposes is due to the innate 
properties of the material to have good biocompatibility and low immunogenicity in the 
native environment. However, other properties such as mechanical properties and 
degradation rate/products must also be compliant with the tissue because it is still 
possible for an immune response to occur. With this in mind a couple of groups have 
explored the possibility of using fibroin as a biomaterial for a NP scaffold replacement. 
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Silk fibroin has been chosen for research as an NP replacement due to high similarity in 
terms of biochemical composition.46  
Current studies utilizing silk fibroin process the material using freeze-drying 
paraffin-sphere-leaching in order to create pores within the scaffold (Figure 1.4).46,47 
Scaffolds were then examined for cell viability and mechanical properties. From initial 
studies Zeng proved cells were able to not only survive but were able to proliferate on the 
construct. They also depicted significant increases in proteoglycan, collagen type II, and 
compressive elastic modulus of their cell seeded scaffolds out to three weeks culture 
time.46 However, even though proteoglycan content had significantly increased, it had 
only increased to ~50ng/mL this is orders of magnitudes lower than what is present in 
healthy native NP, ~200-400µg/mg48, as well as the GAG: HYP ratio was approximately 
2: 1 throughout the experiment which is more similar to cartilage throughout the body but 
not in the NP where the ratio is 27: 1 GAG: HYP. 6,46 
 
Figure 1.4: Example procedure of forming a silk fibroin scaffold.47 
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1.5.2.2 Injectable Scaffolds for NP Regeneration 
Due to ease of procedure the investigation of using an injectable hydrogel has 
been heavily researched. The uses of alginate and collagen-hyaluronic acid (HA) 
scaffolds have been of interest to several groups. Alginate has been used for its low 
toxicity, low cost, and spontaneous gelation.44,49 The use of a collagen-HA scaffold is due 
to the fact that the native NP is primarily consistent of collagen type II and GAGs.50 
Since these are able to gel when desired they have been investigated as a minimally 
invasive procedure to treat IDD. 
The use of alginate based hydrogels have proven to be effective in cell 
encapsulation and having similar aggregate moduli compared to native human NP.44,49 
However, through examination of literature and current capabilities these alginate 
hydrogels fall short in many aspects of comparing to human NP. GAG content through 
studies conducted by Foss and Chou have shown the inability of proteoglycan production 
to be established even after a 28 day cell study, with GAG content never increasing past 
30µg GAG/mg dry weight tissue. Additionally the % water content tested by Foss after a 
28 day study on their cell seeded scaffolds was ~13% whereas in healthy human NP it is 
closer to 65%.26,49 Therefore, while alginate scaffolds can gel fast and allow for cell 
viability and proliferation they are unable to motivate cells into an NP-like phenotype 
with the lack of GAG production. 
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1.5.2.3 Decellularization for NP Regeneration 
Lastly, scaffold development via decellularization has also been explored and 
brings its own advantages and disadvantages.  Decellularization is a process in which 
cells and antigens are removed via chemical and physical means to leave a scaffold 
composed of native ECM. Ideally a decellularized scaffold would have no remnants of 
cells and maintain the majority of the ECM however, current literature depicts the how 
difficult this is to achieve.51 A balance must be achieved between maintaining the native 
ECM and removal of xenogeneic properties. Several animal sources have been used as a 
base scaffold for decellularization, porcine and bovine.43,45,52,53 
The utilization of a porcine model for decellularization must ensure the removal 
of an antigen known as α-gal, which causes a severe immune response within the host. 
Previous work by Mercuri, et al., has shown the removal of this epitope while still 
maintaining the majority of the natural ECM. However, while the majority of the native 
ECM was retained the mechanical properties of the tissue were significantly lower than 
that of native human NP. Additionally, during extended cell culture experiments the 
tissue lost a majority of the native GAG content due to GAG leaching into the media.  
 The use of bovine caudal IVDs however does seem promising as a platform for 
decellularization. Biochemically before decellularization the NPs start with nearly double 
the amount of GAG content, 800µg GAG/mg tissue dry weight, than human NP and also 
have very low presence of DNA. Chan et al has shown the use of decellularizing the 
entire caudal bovine IVD as a use for a xenogenix scaffold replacement. While they are 
able to retain a majority of the native ECM, they were only able to devitalize the cells 
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within the scaffold and were unable to fully remove them from the tissue.53 This is 
concern due to the simple issue of dead xenogeneic cells still present on a scaffold can 
still illicit and immune response.54 Additionally, Iatridis group has developed an 
injectable decellularized bovine scaffold for NP treatment. However, these scaffold that 
were created failed to even retain greater than 100µg GAG/mg tissue dry weight. 
Additionally, the collagen presence within the tissue was greater than 400µg collagen 
type II/mg dry weight, indicating an inverse ratio of GAG: HYP within their tissues 
whereas in healthy native NP GAG is significantly greater than collagen. Additionally, 
these scaffolds were minced and injected via a 25G into an injury site, it would therefore 
be fair to assume that this type of scaffold would be unable to support any mechanical 
load experienced within the disc, therefore would fail in both aspects of biochemical 
composition and mechanical integrity.  
 
1.5.3 Current Animal Models 
A multitude of animal models have been utilized to test therapies for IDD. 
Current animal models include and are not limited to mice, rats, rabbits, canine, porcine, 
ovine, caprine, and non-human primates. Although there are numerous options in animal 
selection, it must be done with care and data should be observed cautiously due to 
intrinsic differences between animals and humans (IVD size and aspect ratio, variations 
in cell population, biomechanics, biochemistry, and variations in anatomical structures).   
 Currently the most widely used established models are in rats and rabbits. 
Investigators looking to obtain valuable clinical information should be wary using these 
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animal models however; this is due to the disc space being too small to be of clinical 
use.55,56 For clinical relevance a large animal model needs to be used in order to at least 
obtain physiological numbers that are more similar to humans. Additionally the disc 
space is much larger in larger animal models therefore allowing the implantation of a 
material scaled appropriately to the animal. Currently a new model has been 
characterized and established using a caprine model. This model allows for the use of 
either the cervical or lumbar spine. This model can induce a steady degeneration with the 
use of a chondroitinase-ABC solution, or artificially by performing a nucleotomy.57–61 
 
1.6 Summary 
NPs are structures specialized for supporting and resisting compressive loads 
while also providing stability and flexibility to the entire spinal motion segment. 
Unfortunately due to several factors the disc undergo severe degeneration that primarily 
begins within the NP. The culmination of this degeneration leads to mechanically 
compromised IVDs and detrimental changes in adjacent discs leading towards pain and 
significant socio-economic burdens. Current treatment of this condition fails to address 
the cause this pathology and merely mitigate the pain. Areas of research aim to further 
expound upon the degenerative process and develop novel treatment strategies to 
mitigate, halt, or even reverse this degenerative process. The ideal NP replacement would 
be of a material that is similar to healthy human NP in regards to biochemistry and 
biomechanical properties, which could be used in an early stage intervention to slow or 
halt the degeneration.  
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The paradigm of tissue engineering is the utilization of cells, scaffolds, and 
soluble factors as a means to provide an effective method of creation of a NP 
replacement. The utilization of stem cells is the most promising cell source for a NP 
tissue-engineering scaffold because and autologous or allogeneic source of NP cells 
would cause more harm than healing. With regards to scaffold creation it is necessary 
that it is capable of mimicking the biochemical/mechanical properties of the native 
human NP. The recreation of the natural human NP properties can be done either by 
incorporating ECM components or utilizing xenogeneic sources. While there is no single 
correct answer to the issue the utilization of a decellularization method on a NP tissue 
does seem the most promising. Decellularization has the key advantages of already 
having the natural ECM present needed to guide stem cells down certain pathways and 
also retain endogenous factors that have been shown to guide differentiation, cell 
migration, and proliferation.51 The caveat with this method of scaffold development is the 
balance that must be maintained in the removal of xenogeneic material while also 
maintaining the majority of ECM components. 
 In conclusion, an ideal scaffold should be consistent of the primary ECM 
components in the proper concentrations similar to those found in native human NP 
ECM. This would most likely result with a scaffold with comparable 
biochemical/mechanical properties compared to native human NP. Accordingly, the 
implantation of such a device would allow for the restoration of mechanical function to 
the spinal unit without significant issues. Additionally, a scaffold of this nature would 
also serve as an ideal carrier of stem cells that could differentiate in to healthy NP-like 
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cells prior to implantation. This would allow for the eventual remodeling of tissue and 
incorporation into the human NP post implantation. In view of this information, the work 
described in the following thesis focus on the development and characterization of a 
novel biomaterial to be used as an ideal scaffold for tissue engineering the nucleus 
pulposus of the human IVD. 
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CHAPTER TWO 
MATERIAL AND METHODS 
 
2.1 Tissue Harvest 
Caudal IVDs from skeletally mature bovines aged from 2-3 years old were 
obtained from a local abattoir and transported on ice to the facilities. Betadine® was 
applied to the exterior of the tail to minimize any present bacteria on the tissue. The tails 
were then removed of excess flesh and muscle via the use of a scalpel blade in order to 
locate the discs within the tails. Once located loppers were used to cut superior of the disc 
and inferior to the endplate to expose the whole disc. An 8 mm biopsy punch and a 
scalpel blade were used in conjunction to remove the NP from the IVD. Fresh samples 
were placed in an empty specimen container and stored at -20˚C to serve as controls for 
all experiments. Samples for decellularization, except treatment groups 8-10, were placed 
in a specimen container containing one of the formulations of decellularization (decell) 
solution, whereas specimens for treatment groups 8-10 were placed in ethanol (EtOH) 
(Table 1). 
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Table 1: A detailed table of all treatment groups tested describing physical means and solution formation. 
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2.2 Decellularization and Nuclease Solution Creation 
 All decell solutions were made they day prior to use within the study. All 
solutions except for Decell 11 (Table 1) were made in a 50mM Tris, whereas Decell 11 
was made in 2.21 mM EDTA and 1x PBS. Decell solutions also were made up of 2% 
antibiotic/antimycotic (AB/AM) Nuclease solution for each group was made the day of 
and all were created in 1x PBS and 5mM Magnesium Chloride.  
 
2.3 Decellularization Optimization 
The decellularization process that is being optimized is of decell method and 
solution (Treatment Group 6) adapted from Mercuri et al.45 Briefly this decell 
procedure calls for samples to be placed in containers containing decell solution and 
sonicated for 10 minutes once every 24 hours over a 72 hour period and placed on an 
orbital at 150 RPM for 72 hours with solution changes occurring every 24 hours. After 72 
hours samples are placed in dH2O, sonicated for 10 minutes and then placed on an orbital 
shaker at 150 RPM for the duration of one hour. Following the hour in dH2O samples are 
then placed in 70% ethanol for 30 minutes then washed again in dH2O for 30 minutes all 
while on the orbital shaker. Samples are then placed in a nuclease solution at 37˚C for 48 
hours. After 48 hours samples are then washed for 1 hour in dH2O with solution changes 
every 30 minutes. The changes made to this procedure and solutions (as seen in Table 1) 
were to the total time in decell solution, total number of sonication, concentrations and 
make up of both decull and nuclease solutions, treatment with SDS, and the use of 
pretreatment in EtOH.  
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Thirteen different treatment groups were established (Table1) and were screened 
by measuring the DNA content and glycosaminoglycan (GAG) of the treated tissues. The 
assays used to identify DNA and GAG content was a PicoGreen® assay and agarose gel 
electrophoresis for DNA and a dimethymethylene blue assay (DMMB) for GAG. The 
determination of successful removal of DNA for decelularization of the samples was 
established to contain less than 50 ng/mg DNA per tissue dry weight and less than 200 bp 
DNA fragment length.51 However, there must be a balance of removal of DNA and 
maintaining the natural ECM, therefore at least 200µg/mg GAG per dry weight tissue 
was established as the guideline for maintaining enough natural ECM. Lastly, histology 
was employed to observe any remaining cell remnants within samples and to qualitatively 
evaluate the GAG content. When the above criterion was met acceptable treatment 
groups continued for further evaluation and characterization.  
 
2.4 Biochemical Analysis 
 Cross sections from all samples from decell treatment groups and fresh tissue 
were stored at -80˚C overnight and lyophilized for two days. Samples were then digested 
in a PBE buffer containing Papain (5mM L-Cysteine, 100mM Dibasic Phosphate Buffer, 
5mM EDTA, 125µg/mL Papain, pH 6.5) for 24 hours at 65˚C and were vortexed 
periodically until the tissue was fully digested. All values obtained were normalized to 
tissue dry weight.  
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2.4.1 PicoGreen® Analysis for dsDNA 
 Total DNA content of fresh bovine NPs (n=6) and treatment groups 1-13 (n=6) 
were quantified using a PicoGreen® assay. Papain samples were first diluted by 2x in a 
1X TE buffer, and then 100µL of this mixture was taken and added to a black-well well 
plate in order to prevent fluorescent bleaching and interference from other samples in 
adjacent wells. Next 100µL of the PicoGreen® reagent was added to each well containing 
solution and incubated in the dark for 5 minutes. The plates were then read at an 
excitation of 480nm and emission of 520nm. DNA (expressed as DNA ng/mg sample dry 
weight) was determined using serial dilutions of a known DNA content provided within 
the PicoGreen® kit.  
 
2.4.2 Agarose Gel Electrophoresis 
 In order to observe if there were any residual base pairs of DNA remaining the 
papain digested samples of both fresh (n=3) and treated (n=3) NPs first purified using a 
Qiagen DNeasy® Blood & Tissue extraction kit in accordance with the protocol provided 
by the manufacture. The DNA was visualized using an ethidium bromide agarose gel. All 
samples were compared to a DNA standard to determine the size of the remaining base 
pairs of DNA present within the tissue. In order to cover a wide range of base pairs two 
separate gels were created.  A wide range ladder (300-24,000bp, exACTGene 24kb) was 
used in a 1% agarose gel and was run at 100V for 60 minutes. A low range ladder (10-
300bp, O’GeneRuler Low Range DNA) was used in a 5% agarose gel and was run at 
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75V for 60 minutes. Gels were then imaged in a bio-imager using an ethidium bromide 
filter to detect the DNA bands.  
 
2.4.3 DMMB Analysis for GAG 
 Papain digested samples of fresh (n=6) and treated (n=6) NPs were diluted by 
1000x and 100x respectively in PBE buffer (5mM L-Cysteine, 100mM Dibasic 
Phosphate Buffer, 5mM EDTA, pH 7.5). From this mixture 50 µL’s were taken and 
added to a 96-well plate, then 200µL of DMMB reagent (40mM NaCl, 40mM Glycine, 
46µM DMMB, pH 3.0) was added to each well containing either sample or standard. The 
plates were then read at an absorbance of 525 nm. GAG (expressed as GAG µg/mg 
sample dry weight) was determined via a standard curve developed from different 
dilutions of known concentrations of chondroitin sulfate.  
 
2.4.4 Hydroxyproline Analysis 
 Fresh bovine NPs (n=3) and treated NPs (n=6) had their collagen content 
quantified by using a hydroxyproline (HYP) assay following the manufacturers protocol 
(Sigma – MAK008) with the addition of a dilution step after charcoal purification. The 
supernantent of both fresh and treated NPs were diluted in 12M HCl to create a 100x total 
dilution. HYP content (expressed as [HYP] µg/mg sample dry weight) was calculated 
using a standard of serial dilutions of a known concentration of HYP provided in the kit 
with the optical absorbance being read at 550nm. 
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2.5 Histology and Immunohistochemistry (IHC) 
 Cross sections of both fresh bovine NPs and treated NPs were fixed in 10% 
neutral buffered formalin for 24 hours. Fixed samples were then washed in 1X PBS with 
0.01% sodium azide for 30 minutes. Tissues were then soaked in a 15% sucrose solution 
at 4˚C overnight. After soaking samples were placed in a 30% sucrose solution for 2 
hours at 4˚C, then were placed in a 50/50 30% sucrose and OCT solution for 2 hours at 
room temperature. Lastly, samples were placed in OCT for 2 hours then transferred to 
OCT molds for cryosectioning at -20˚C until solid. Cryosections were then sectioned at 
8µm and were attached to positively charged slides and stored at -20˚C until needed for 
staining. All slides were imaged using a Zeiss Axio Vert.A1.  
 
2.5.1 IHC for Collagen-II 
 Frozen sections of both fresh (n=3) and treated (n=3) NPs were fixed for 20 
minutes in cold acetone. Slides were then processed according to the provided protocol 
for the Vectastain® ABC Elite Kit Rabbit IgG and DAB substrate kit (SK4100). The 
antibody used for detection was a rabbit polyclonal to collagen-II specific for bovine 
(Abcam – ab78482). Sections were developed in DAB for 5 minutes, washed and then 
counterstained in a 50/50 hematoxylin/water solution for 30 seconds. Sections were then 
rinsed, dehydrated, cleared, and mounted.  
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2.5.2 Alcian Blue Counterstained with Nuclear Fast Red 
 Frozen sections of both fresh (n=6) and treated (n=6) NPs were rinsed in tap 
water until sheeting occurred. Samples were then placed in 3% acetic acid for 1 minute 
then placed in 1% alcian blue in 3% acetic acid (pH 2.5) for 3 minutes. Slides were then 
rinsed in tap water for 1 minute and then rinsed in distilled water until clear. Sections 
were then counterstained in 0.1% nuclear fast red for 2 minutes, rinsed in tap water for 1 
minute, then dehydrated mounted and coverslipped.  
 
2.5.3 DAPI 
 Frozen slides of both fresh (n=3) and treated (n=3) NPs were rinsed in 1X PBS 
for 1 minute then placed in a 300nM DAPI solution for 5 minutes in the dark. Slides were 
then washed in PBS and were transported for imaging under a fluorescent microscope 
immediately. 
 
2.5.4 Ethidium Bromide Staining 
 Tissues for both fresh (n=3) and treated (n=3) NPs were placed in a mixture of 
4mM Calcein AM and 2mM Ethidium Bromide-III in PBS for 30 minutes. Tissues were 
then thinly sectioned using a scalpel blade and imaged under a fluorescent microscope.  
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2.6 Mechanical Testing 
 Both tissues were frozen at -20˚C and then placed in an OCT mold and sectioned 
to a thinckness of ~2µm for all testing. Samples were then allowed to thaw and free swell 
in the testing tank solution consisting of 1X PBS and 1% protease inhibitor. All testing 
was performed on a Bose Electrofoce® 3200 series with a 1000g load cell.  
 
2.6.1 Unconfined Compression 
 Unconfined compression was used to conduct a stress relaxation experiment to 
determine the equilibrium modulus and percent relaxation was adapted from multiple 
sources.9,26 Specimens were allowed to free swell for 30 minutes and then were placed in 
between two non-porous platens. Samples were then loaded to 2.5N and were allowed to 
reach equilibrium. Once the sample was equilibrated the height was recorded and used as 
the initial height for testing, this was done for each individual sample. The strains that 
were tested were 8%, 12%, and 16%.  Strains were applied instantaneously and samples 
were allowed to relax for 20 minutes (the determined equilibrium from previous trials) 
until the next strain was applied. Data was collected using level crossing with each 
∆0.025N being recorded.  
 
2.6.2 Unconfined Dynamic Mechanical Analysis (DMA)  
 DMA testing was used to determine the complex, storage, and loss modulus and 
phase angle of both the fresh bovine NP and treated scaffolds. Similarly to unconfined 
compression samples were loaded to 2.5N and height was obtained at equilibrium. 
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Samples were preconditioned at 5% strain for 10 cycles. The height and width of each 
sample was placed into the DMA program and was set to run at 0.01, 0.1, 1, and 10 Hz 
with a 20-minute relaxation between frequencies. Once testing was concluded the 
program calculated the desired values.  
 
2.7 Cell Studies 
2.7.1 Scaffold Cytotoxicity 
Scaffolds were first sterilized in 0.01% paracetic acid then washed three times at 
15 minutes each in 1X sterile PBS. Scaffolds were then placed in a solution of 50% FBS, 
48% DMEM, and 2% AB/AM for 24 hours. Human amniotic mesencymal stem cells 
(hAMSCs) were seeded at a density of 2,000 hAMSCs/mm2 for each scaffold. Once 
seeded scaffolds were incubated for 3 hours to allow time for cells to settle and integrate, 
once 3 hours were over standard media was added to each well. On days 3,7 and 14 a 
live/dead assay was performed (n=3, time point). A Viability/Cytotoxicity assay for 
live/dead cells kit was used and performed following the manufactures instructions. 
Seeded scaffolds were then thinly section using a scalpel blade and imaged under a 
fluorescent microscope. Three images of both live and dead were then taken for each 
scaffold. Counts of cells were performed by manually counting live and dead cells. 
Percent viability was determined by dividing the difference of live and dead cells over the 
amount of live cells.  
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2.7.2 Scaffold Crosslinking 
 ABNP scaffolds crosslinked in 30:6 EDC: NHS for 30 minutes. Scaffolds were 
then washed three times for 15 minutes each. After washing scaffolds were sterilized 
utilizing the method previously mentioned in 0.1% paracetic acid and placed in a solution 
of 50% FBS, 48% DMEM, and 2% AB/AM for 24 hours.  
 
2.7.3 Syringe Gauge Viability Study 
 In order to determine the best syringe to use for cell injection different sized 
gauges were evaluated to determine the viability of cells after passing through the 
syringe. Cells were aliquoted into 1mL amounts to create a 1 x 106 cells/mL solution into 
1.5mL microfuge tubes. First a 21G was utilized, if cells had high viability than a higher 
gauge syringe would be tested and vice versa, to suck up the solution and then was 
injected into a separate tube. The injected solution was tested using a trypan blue 
detection method and viability was determined. If the viability was high than a 28G 
needle would be tested and if the viability was low a 16G needle would be tested. The 
purpose of this is to best determine the smallest syringe size to inject cells into ABNP 
scaffold.  
 
2.7.4 Cell Injection Study 
 Similarly to the cytotoxicity study scaffolds were sterilized and were stored in a 
50/40/2 solution of FBS/ DMEM/ AB/AM. A seeding density of of 2,000 hAMSCs/mm2 
for each scaffold was also used. Scaffolds were injected in 3 separate areas using a 28G 
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syringe. Each scaffold could be filled with 100-150µL of the cell solution and the 
remainder was seeded directly onto the scaffold. After seeding scaffolds were placed in a 
24-well plate for 3 hours to allow cells to settle and integrate into the scaffolds before 
media was added to the wells. On days 3 and 14 scaffolds underwent live/dead staining to 
determine % viability and also were processed for frozen sectioning to stain for cell 
penetration.  
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CHAPTER THREE 
RESULTS 
 
3.1 Decellularization Optimization Screening Analysis 
 
The effectiveness of all decellularization groups were screened by measuring the 
GAG and DNA content of the tissues to evaluate the maintenance of this critical 
extracellular matrix component while efficiently removing cellular remnants. The 
decellularization procedures utilized and screening results are summarized in Table 3.1. 
Optimized treatment groups were defined as those that maintained at least 200µg/mg of 
GAG and less than 50ng/mg DNA.   
From the initial testing of treatment groups 1-9 there were significant differences 
with all groups when compared to fresh bovine NP for both GAG retention and DNA 
removal (Figure 3.1A, 3.2A), additionally there were significant differences found 
among treatment groups (Figure 3.1B, 3.2B). Treatment group 9 significantly retained 
more GAG (235.03 ± 56.44 µg GAG/mg tissue dry weight) than treatment groups 1-6. 
Treatment groups 7 and 8 however, were not significantly different, 131.55 ± 19.26 and 
123.15 ± 30.86µg GAG/mg tissue dry weight respectively, from treatment group 9 with 
respect to GAG content. Although all treatment groups had less than 16ng DNA/mg 
tissue dry weight there were significant differences between groups (Figure 3.2B). 
Treatment groups 2 and 8 had the largest values of DNA still present, 15.26 ± 5.85 and 
15.6 ± 2.9DNA/mg tissue dry weight respectively, and therefore had significant 
differences with groups that were able to remove higher amounts of DNA. Treatment 
groups 7 and 9 as well as treatment group 8 were able to retain the most GAGs and were 
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therefore groups of interest for DNA removal. The DNA content for both treatment group 
7 and 9 was 8.44 ± 2.14 and 9.08 ± 0.39ng DNA/mg tissue dry weight respectively. 
Although treatment group 9 seemed like the ideal candidate as an optimal 
decellularization procedure macroscopically the tissue seemed to harden and lost its gel-
like properties, whereas treatment group 8 was still a gel-like material. With this 
information on both GAG and DNA content, as well as a histological assessment (Figure 
3.3) treatment group 7 and a combination of treatment groups 8 and 9 were chosen to 
quantify, due to the ability of these groups retention of the most GAG content while still 
removing a significant amount of DNA. 
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* A 
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Figure 3.1: (A) Quantification of GAG content of treatment groups compared to fresh bovine NP 
(p>0.05) (B) Quantification of GAG content of treatment groups compared to each other (p>0.05) 
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* A 
B 
 
Figure 3.2: (A) Quantification of DNA content of treatment groups compared to fresh bovine NP 
(p>0.05) (B) Quantification of DNA content of treatment groups compared to each other (p>0.05) 
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Figure 3.3: Alcian blue counter-stained with nuclear fast red histology. Blue depicts GAG and Red/Purple 
depicts cell nuclei. (A) 200x (B) 400x image of treatment group 1 (C) 200x (D) 400x image of treatment 
group 4 (E) 200x (F) 400x image of treatment group 7 (G) 200x (H) 400x image of fresh bovine NP 
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A second optimization study was performed to expand numbers for treatment 
group 7, with the additions of 45-minute ethanol prewash, hypothesized from previous 
observations that ethanol dehydrates the scaffolds allowing for more decellularization 
solution to be absorbed by the scaffold during treatment. Additionally, another treatment 
group was created to observe the result of removing deoxycholic acid from the base 
formula of decellularization previously described. The choice to remove deoxycholic acid 
from the base decellularization solution was hypothesized that the ionic nature of the 
component was disrupting too much of the native ECM during the decellularization 
procedure. From this the only significant differences observed were from the tissue 
compared to the treatment groups for GAG retention and DNA removal (Figure 3.4, 3.5). 
All treatment groups had less than 25ng DNA/mg tissue dry weight additionally both 
treatment groups 7 and 10 had higher than 200µg GAG/mg tissue dry weight with 
treatment group only maintaining ~187µg of GAG (Figure 3.4). However, from 
histology treatment group 11 had stained more intensely blue, indicating higher GAG 
concentration, than treatment groups 7 and 10 (Figure 3.6). Therefore an additional 
round of optimization was decided upon to test a high concentration of decellularization 
solution without the deoxycholic acid component, this is due to the histology of treatment 
group 11 and that treatment group 11 was not significantly different from treatment 
groups 7 and 10. In addition, a SDS decellularization group, treatment group 12, was 
added to compare how our decellularization solution compares against a widely used 
method of decellularization.  
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Figure 3.4: (A) Quantification of GAG content of treatment groups compared to fresh bovine NP (p>0.05) 
(B) Quantification of GAG content of treatment groups compared to each other (p>0.05) 
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Figure 3.5: (A) Quantification of DNA content of treatment groups compared to fresh bovine NP (p>0.05) 
(B) Quantification of DNA content of treatment groups compared to each other (p>0.05) 
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Figure 3.6: Alcian blue counter-stained with nuclear fast red histology. Blue depicts GAG and Red/Purple 
depicts cell nuclei. (A) 200x (B) 400x image of treatment group 7 (C) 200x (D) 400x image of treatment 
group 10 (E) 200x (F) 400x image of treatment group 11 (G) 200x (H) 400x image of fresh bovine NP 
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A final study was performed to ensure there was at least an n=6 for all treatment 
groups. All treatment groups, except for treatment group 12 (SDS), were able to retain 
greater than 200µg GAG/mg tissue dry weight with only treatment group 12 being 
significantly different from the other groups (Figure 3.7). Interestingly, all groups except 
for treatment group 12 had lower than 35ng DNA/mg tissue dry weight with treatment 
group 13 only having less than 10ng DNA/mg tissue dry weight remaining. Treatment 
group 12 however had greater than 70ng DNA/mg tissue dry weight remaining within the 
tissue (Figure 3.8). Additionally the histology for treatment group 13 depicted intact 
empty lacunae (Figure 3.9). Accordingly, three decellularization treatment groups (7, 10 
& 13) were selected based on the criterion set prior (Table 1). Additional characterization 
to confirm the removal of residual DNA fragments was evaluated via agarose gel 
electrophoresis.  
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Figure 3.7: (A) Quantification of GAG content of treatment groups compared to fresh bovine NP (p>0.05) 
(B) Quantification of GAG content of treatment groups compared to each other (p>0.05) 
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Figure 3.8: (A) Quantification of DNA content of treatment groups compared to fresh bovine NP (p>0.05) 
(B) Quantification of DNA content of treatment groups compared to each other (p>0.05) 
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Figure 3.9: Alcian blue counter-stained with nuclear fast red histology. Blue depicts GAG and Red/Purple 
depicts cell nuclei. (A) 200x (B) 400x image of treatment group 7 (C) 200x (D) 400x image of treatment 
group 10 (E) 200x (F) 400x image of treatment group 12 (G) 200x (H) 400x image of treatment group 13 
(I) 200x (J) 400x image of fresh bovine NP 
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3.2 Biochemical Analysis of Optimal Decellularization Treatments 
3.2.1 DNA Quantification 
Evaluation of double stranded bovine DNA demonstrated significant reductions 
(p<0.01) in treatment groups 7, 10, & 13 as compared to fresh tissue.  These groups, with 
no significant differences between them, contained 33.61 ± 9.49ng, 33.08 ± 11.57ng, and 
9.07 ± 1.95ng DNA/mg sample dry weight, respectively (Figure 3.8B). Interestingly, 
samples treated with SDS did not show significant reductions in DNA content, which 
contained 71.31 ± 30.59ng DNA/mg dry weight. Compared to the DNA within fresh 
bovine NPs (125.45 ± 11.81ng DNA/mg sample dry weight) there was a 73.2 ± 7.56%, 
73.63 ± 9.22%, & 92.77 ± 1.54% reduction in DNA content in treatment groups 7, 10, 
and 13 respectively.  
 
3.2.2 Qualitative Measurement of DNA 
Detection of DNA fragments ranging from 10-24,000bp was evaluated for 
treatment groups 7, 10, and 13 and compared to fresh bovine NP samples. No visible 
bands were observed in either agarose gel for treatment groups 10 and 13 indicating no 
residual DNA fragments, whereas DNA bands were visible for fresh and treatment 7 
(Figure 3.10).  
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Figure 3.10: Agarose gel electrophoresis depicting the presence of DNA in fresh bovine NP and in 
treatment group 7 (white box), and the lack of DNA fragments in treatment groups 10 and 13 tested from 
10-24,000bp. 
 
3.2.3 GAG Quantification 
GAG quantification of decellularized bovine NP, with no significant differences 
between groups, demonstrated the retention of 216.98 ± 31.06µg, 2018.93 ± 24.96µg, 
71.92 ± 5.18µg, and 205.5 ± 16.00µg GAG/mg sample dry weight within treatments 7, 
10, and 13 respectively (Figure 3.7B). These values were statistically different when 
compared to fresh bovine NP tissue (677.66 ± 93.22 µg GAG/mg sample dry weight) 
(Figure 3.7A). SDS treatment resulted in dramatic reduction in GAG content (71.92 ± 
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5.18µg) compared to treatments 7, 10, and 13. Decellularization resulted in an average 
reduction GAG content of 67.98 ± 4.58%, 69.17 ± 3.68%, & 69.68 ± 2.36% in treatment 
groups 7, 10, and 13 respectively. Taken together with the aforementioned data treatment 
group 13 was selected as the optimal decellularization method investigated herein, thus 
further biochemical, histological and mechanical analysis was performed on samples 
subjected to this treatment group (highlighted in Table 1). 
 
3.2.4 Hydroxyproline Quantification 
Hydroxyproline (HYP) quantification on samples treated with procedure 13 had 
significantly higher HYP content per dry mass as compared to fresh bovine NP tissue 
(p<0.05) (Figure 3.11). Treatment group 13 contained nearly double the average amount 
of hydroxyproline as compared to fresh bovine NPs (13.87 ± 1.14µg & 8.63 ± 0.24µg 
HYP/mg sample dry weight). Additionally, the GAG to HYP ratio was calculated to be 
approximately 15:1 for decellularized samples whereas, fresh bovine NP tissue had an 
apparent ratio of 79:1. 
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Figure 3.11: Hydroxyproline assay quantification of [HYP] content found in treatment group 13 and fresh 
bovine NP demonstrating a significant increase (*p<0.05) in [HYP]. 
 
3.2.5 IHC for Collagen-II 
IHC for collagen type 2 (Col-II) confirmed the presence of Col-2 within both 
treatment group 13 and fresh bovine NP. Histological images illustrated intense brown 
(positive) staining in both groups as compared to negative controls (Figure 3.12). 
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Figure 3.12: Immunohistochemistry for Col-II tissue from treatment group 13 (A) 200x (B) 400x 
compared to fresh tissue (C) 200x (D) 400x. Inserts are negative controls. 
 
3.2.5 Macroscopic & Histological Evaluation 
Macroscopically both fresh bovine NPs and the NPs from treatment 13 
maintained their shape and exhibited a hydrated status (76.58 ± 1.4% and 94.56 ± 0.37% 
percent water content respectively) (Figure 3.13). Qualitative histology of the fresh 
bovine NPs depicted the presence of cells in clusters / islands. The fresh bovine NPs also 
stained more intensely with alcian blue as indicated by a deeper blue staining as 
compared with the treatment 13 NPs (Figure 3.9). Within the matrix of the treatment 13 
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NPs it is clearly visible that there exist empty lacunae with no visible cell remnants. 
DAPI staining was performed to re-confirm the lack of cell nuclei present in the 
treatment 13 NPs (Figure 3.14). The presence of nuclear material is clearly evident in the 
fresh bovine NP. The treatment 13 NPs not only depicts no fluorescence of nuclear 
material but also depicts empty lacunae further re-confirming the removal of nuclear 
material. Lastly, an ethidium bromide (EtBr) stain was used to once again confirm the 
lack of residual DNA within the treatment 13 NPs (data not shown). Therefore with this 
confirmation of complete cell removal the treatment 13 NPs were hereafter referred to as 
acellular bovine nucleus pulposus (ABNP) scaffold. 
 
Figure 3.13: Macroscopic image of (left) fresh bovine NP and (right) an NP from treatment group 13. 
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Figure 3.14: DAPI staining to induce fluorescence of cell nuclei. (A) 200x (B) 400x image of treatment 
group 7 (C) 200x (D) 400x image of treatment group 10 (E) 200x (F) 400x image of treatment group 13 
(G) 200x (H) 400x image of fresh bovine NP 
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3.3 Mechanical Analysis 
3.3.1 Unconfined Compression  
Equilibrium modulus, and percent relaxation of both ABNP scaffolds and fresh 
bovine NP were determined by unconfined compression stress relaxation testing (Figure 
3.15). These values for the ABNP scaffold were determined to be 5.6 ± 1.12kPa and 
82.26 ± 3.7%. The values for fresh bovine NP were determined to be 50.75 ± 6.97kPa 
and 78.01 ± 3.81%, respectively (Table 2).   
Property ABNP Fresh Bovine
% Water Content (%) 94.56 ± 0.37 76.58 ± 1.47
Equilibrium Modulus (kPa) 5.6 ± 1.12 7.08 ± 0.64
% Relaxation (%) 82.26 ± 3.7 78.01 ± 3.81  
Table 2: Values obtained from unconfined compression testing 
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Figure 3.15: (A) ABNP (B) Fresh Bovine NP. Representative curve of stress relaxation during unconfined 
compression testing. Peaks are at 8, 12, & 16% strain respectively. 
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3.3.2 Dynamic Mechanical Analysis (DMA) 
The complex, storage, and loss moduli as well as the phase angle of the ABNP 
scaffolds and fresh bovine NPs were evaluated and compared using DMA (Table 3).  No 
statistical difference was observed when comparing both groups. There did appear to be a 
frequency dependent relationship for both sample types. The range of values observed for 
ABNP scaffold for the complex, storage, and loss moduli and phase angle were 6.3-
13.5kPa, 6.3-13.5kPa, 1.6-4.7kPa, and 14.9-26˚, respectively over the frequencies tested 
(Figure 3.16A-B). Fresh bovine NP values tended to be similar compared to ABNP and 
were found within the ranges of 6.36-13.99kPa, 5.99-13.13 kPa, 2.12-4.55kPa, and 
15.36-20.16˚, respectively (Figure3.16C-D).  
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Frequency 0.01 0.1 1 10
Frequency 0.01 0.1 1 10
Frequency 0.01 0.1 1 10
Frequency 0.01 0.1 1 10
ABNP
Fresh
Fresh
6.59 ± 1.64
6.36 ± 1.13
8.02 ± 1.96 9.96 ± 2.22
Complex Modulus (kPa)
Storage Modulus (kPa)
Loss Modulus (kPa)
Phase Angle (Degree)
ABNP
ABNP
Fresh
ABNP
Fresh
16.66 ± 1.59
13.52 ± 2.82
6.35 ± 1.62 7.85 ± 1.92 10.25 ± 2.65 12.11 ± 2.85
1.68 ± 0.29
18.90 ± 2.37
26.44 ± 3.53
8.56 ± 1.4 10.92 ± 1.59 13.99 ± 2
5.99 ± 1.11 8.23 ± 1.38 10.51 ± 1.56 13.13 ± 1.9
2.12 ± 0.3 2.29 ± 0.36
1.83 ± 0.32 2.45 ± 0.41 4.8 ± 0.89
17.3 ± 1.34 14.99 ± 1.17
2.86 ± 0.48 4.55 ± 0.83
20.16 ± 1.61 15.93 ± 1.77 15.36 ±  1.96
 
Table 3: Range of values for the viscoelastic properties obtained for both the ABNP and Fresh Bovine NP 
during DMA. 
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Figure3.16: Dynamic mechanical analysis of the ABNP scaffold compared to fresh bovine NP tissue. (A & 
C) Representative curve of the complex (E*), Storage (E’) and Loss (E’’) moduli as well as (B & D) Phase 
angle (δ) of ABNP samples compared to fresh bovine NP tested at 8% strain at different frequencies. No 
significant differences found at any point. 
 
3.4 Cell Studies   
3.4.1 ABNP Cytotoxicity Study 
ABNP scaffold cytotoxicity was evaluated by seeding human amniotic 
mesenchymal stem cells (hAMSCs) onto the surface of the ABNP scaffold and cultured 
to 14 days. Live/dead fluorescence indicated cell viability to be 94%, 87%, and 95% at 
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days 3, 7, and 14, respectively (Figure 3.17). However, there was no noticeable cell 
penetration into the scaffolds throughout the duration of the study. 
 
C B A 
 
Figure 3.17: Live/Dead staining was performed on days 3, 7, & 14 with percent viability at 94, 87, & 95% 
cell viability, respectively. (Top) Graph of the cell viability throughout the study. (Bottom) Representative 
images live/dead stained cell seeded scaffolds. 
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3.4.2 Cell Injection Studies 
Cell injection, via a 28G syringe previously determined as optimal, was 
performed on both ABNP and EDC/NHS (30:6) cross-linked ABNP scaffolds and 
cultured to 14 days. Live/dead fluorescence indicated cell viability at day 3 was 91% and 
73% for the ABNP and cross-linked ABNP scaffold respectively (Figure 3.18). Percent 
viability for day 14 of the ABNP and cross-linked ABNP scaffolds was 97% and 65% 
respectively.  
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Figure 3.18: Representative images of live/dead staining of day 3 of (A) ABNP scaffolds (200x) and (B) 
cross-linked ABNP scaffolds (200x) and day 14 (C) ABNP scaffolds (100x) and (D) cross-linked ABNP 
scaffolds (100x) Red lines are indicative of the syringe pathway. (E) Graph of percent viability of both day 
3 and day 14 ABNP and cross-linked ABNP scaffolds. 
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CHAPTER FOUR 
DISCUSSION 
Ideal methods of decellularization would be capable of removing the majority of 
host cells and their remnants while also preserving the native ECM. Preservation of the 
native ECM is essential since it represents the secreted products of resident cells and has 
been shown to provide cues that affect cell migration, proliferation, and differentiation.51 
However, current methods of decellularization are unable to fully maintain the natural 
ECM while also removing a significant portion of cells.  Considering this, bovine caudal 
IVD NP tissue was chosen for decellularization since the natural ECM has higher 
quantities of GAG when compared to healthy human NP, which varies from 200-600µg 
GAG/mg Dry weight tissue,62 and also have a similar composition, resting stress, and 
height to diameter ratio when compared to human lumbar discs.63 Herein this research 
compares and screens 13 different decellularization conditions and assesses their efficacy 
to decellularize bovine NP tissue while also maintaining the critical NP matrix 
composition. Initial acceptance criteria demonstrating an effective decellularization 
process included the maintenance of NP GAG content of 200µg GAG/mg tissue dry 
weight concomitant with residual DNA content of less than 50ng DNA/mg dry tissue 
weight. It has been suggested that such a low concentration of residual nucleic acid 
should not illicit an immune response.51,62 After passing the initial screening process 
additional methods were used to fully quantify any remaining DNA fragments and cells 
as well as collagen type II content, another critical component of the native NP. 
Additionally, once a single ideal procedure was identified scaffolds from that group 
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underwent a series of mechanical testing, adapting many protocols in literature,9,26,64 to 
thoroughly investigate the viscoelastic properties of the developed material Lastly, it was 
critical for the scaffold developed to allow for the survival and penetration of cells, which 
would play a pivotal role in the regeneration of the NP tissue.  
 
4.1 Decellularization Optimization 
 The utilization of decellularization as a procedure to create a biomimetic scaffold 
does come with it’s own advantages and disadvantages. The challenge associated with 
this type of procedure is the balance of maintaining the ECM while removing all DNA to 
minimize any chance for an immunogenic host response. The preservation of GAG was 
deemed critical for this type of procedure since it is key to the function of the NP, which 
relies upon the osmotic potential that is generated by the GAGs, associated with the 
proteoglycan aggrecan, to create a structure ideal for load distribution.65 Currently, 
groups have shown the retention of the native ECM but only devitalized cells and failed 
to remove cells entirely.53 Additionally, others have also shown the acceptable removal of 
DNA but failed to maintain the majority of the native ECM.43 Groups have used a 
multitude of methods for decellularization including chemical and physical means for 
removal of cells.43,45,51,53 In order to optimize the decellularization procedure different 
solutions, time, and physical means were evaluated in order to determine an ideal 
procedure.  
 From the initial screening study of treatment groups 1-9 several factors were 
evaluated to determine any significant differences amongst groups. All treatment groups 
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were significantly different from the fresh bovine NP controls with respect to DNA 
removal and GAG loss (Figure 3.1, 3.2). Significant differences in regards to DNA 
removal within groups however were interesting. Treatment groups 1 and 2, the only 
difference being amount of sonications, 6 & 12 sonications respectively, were 
significantly different from each other in regards to DNA removal. Treatment group 1, 
even though it experienced less sonications than treatment group 2 had significantly less 
DNA. Additionally treatment group 8, 30-minute ethanol pre-wash, had significantly 
higher DNA, this could be due to the DNA not having enough time to fully precipitate 
out of the scaffold, when compared to treatment groups 1 and 4. Ethanol was initially 
used to provide a method to dehydrate the bovine NPs in order to allow more 
decellularization solution to be absorbed by the tissue but also attributed to GAG 
retention and removal of DNA due to ethanol’s nature to crosslink allowing GAGs to be 
retained without sacrificing the removal of DNA due to ethanol’s ability to precipitate 
DNA out of cells by dehydrating the area around the DNA,66  which worked in the case 
of treatment group 9, however in treatment group 8 the decellularization time and number 
of sonications were lower compared to that of treatment groups 1 and 4, therefore only 30 
minutes in a pre-wash of ethanol was not enough to cut down in decellularization time 
whereas one hour in ethanol was comparable. With regards to GAG retention treatment 
group 9, one hour ethanol wash, was significantly able to retain more GAG than 
treatment groups 1-6 and was comparable to treatment groups 7 and 8. Additionally, 
other trends were noted such as increasing the concentration of the decellularization 
solution was also able to maintain high amounts of GAG while also reducing DNA. 
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There were also no noticeable effects of total time in decellularization and increasing the 
concentration of nuclease solution 
From these initial studies treatment group 7 and a combination of treatment group 
10 utilizing a 45-minute ethanol prewash, which hypothesized from previous 
observations that this median time of ethanol treatment will be enough to allow bovine 
NPs to dehydrate and crosslink long enough to preserve GAG and remove DNA. 
Additionally, treatment group 11 was created to observe the result of removing 
deoxycholic acid; an ionic detergent, from the base formula of decellularization 
previously described. This was decided upon in order to minimize any destruction a 
charged detergent can do to the charged components of the native ECM. From this all 
three groups had no significant differences amongst each other however treatment group 
11, base decellularization solution without deoxycholic acid, trended to have lower 
values of GAG retention and higher DNA removal and also stained more intensely blue 
compared to treatment groups 7 an 10 via histology indicating a more preserved ECM 
matrix (Figure 3.6). Therefore in order to increase GAG concentration a higher 
concentration decellularization solution was utilized with no deoxycholic acid added into 
the solution. Additionally, to compare our formation of deceullularization solution the 
addition of an SDS group was added, since it is a commonly used method of 
decullariaztion.43,53  
From the final optimization of decellularization studies treatment groups 7, 10, 
and 13 all had GAG content greater than 200µg GAG/mg dry weight and DNA content 
lower than 50 ng DNA/mg dry weight (Figure 3.7, 3.8). More impressively treatment 
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group 13 had DNA content lower than 10ng DNA/mg dry weight. Surprisingly treatment 
group 12, the SDS group, had more DNA than some previously treated groups and 
unsurprisingly removed the majority of GAG from the tissue, this however could be from 
a difference of procedure utilized. Observations via histology found that treatment group 
13 was able remove nuclei from the tissue while also maintaining the lacunae (Figure 
3.9G-H). From these studies treatment groups 7, 10, and 13 were selected to continue 
with further confirmation of decellularization using an agarose gel electrophoresis assay 
and DAPI staining.    
 
4.2 Confirmation of Decellularization 
 The removal of cellular components and the confirmation of removal are 
imperative for xenogeneic materials. Even though the healthy IVD is considered an 
immune privilege region, the results of degeneration and surgery can create a site of 
inflammation that should be minimized as much as possible.54 We evaluated this several 
ways and determined that treatment group 13 was the most ideal candidate to continue 
characterizing. Confirmation of the full removal of DNA, DNA fragments, and cells was 
confirmed using a low and high molecular weight agarose gel electrophoresis, and alcian 
blue counterstained with nuclear fast red, DAPI, and ethidium bromide staining. The 
purpose performing an agarose gel was to ensure there were no DNA fragaments greater 
than 200bp left within the tissue since it is generally viewed that DNA containing 
fragments greater than 200bp might still cause an immunogenic response if 
implanted.51,54  
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 The utilization of alcian blue counterstained with nuclear fast red, DAPI, and 
ethidium bromide staining for cell nuclei was performed to observe more clearly any 
remnants of nuclei and confirm no visible presence of cell nuclei which is necessary in 
order to claim a scaffold fully decellulairized.51 All but treatment group 13 had 
observable nuclei within the ECM. Images from treatment group 13 clearly show empty 
lacunae where nuclei would have been prior to decellularization. Therefore with all the 
data considered prior, treatment group 13 will now be referred to as an acellular bovine 
NP (ABNP) scaffold.  
 
4.3 Biochemistry of the ABNP Scaffold 
 As previously discussed the ABNP scaffold was able to retain greater than 200 µg 
GAG/mg tissue dry weight with less than 10ng DNA/mg tissue dry weight. Compared to 
a healthy human NP the GAG content found within ranges from 200-600µg GAG/mg dry 
weight tissue, whereas in severely degenerated human NP the GAG content has been 
reported to be as low as 18µg/mg dry weight and on average 87µg/mg dry weight.62 The 
significant retention of GAG is critical for the maintenance and function of the NP 
tissue.6,18,67 Without high levels of GAG in the NP it will lose its essential function. GAG 
is primarily responsible for creating the osmotic properties and swelling needed to 
transfer compressive loads, but also prevents nerve and blood vessel ingrowth.11,13,15,65 
Also critical to the structure of the NP is the presence of collagen type II and the resulting 
ratio of GAG: HYP.6 Both IHC for collagen type II and a HYP assay were performed to 
evaluate these properties. IHC was able to detect a strong presence for collagen type II 
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and the HYP quantified the concentration to be 13.87 µg HYP/mg tissue dry weight. This 
yields a ratio of approximately 15:1 GAG: HYP, which is lower than what is found 
within a healthy human NP that has a ratio of 27:1 GAG: HYP but higher than an aged 
disc that has a ratio of 5:1 GAG: HYP.6 This ratio however, is much higher than what 
others in literature have been trying to recapitulate.43,68–70  
 
4.4 Viscoelastic Properties of the ABNP Scaffold 
 The viscoelastic properties of the native human NP have been shown to influence 
both the mechanical behavior of the IVD and the mechanics of the entire functional 
spinal unit.4,71 With this in mind, a NP replacement should attempt to mimic or 
reestablish the native properties of the human NP. Compared to native human NP, the 
equilibrium modulus 5.39 ± 2.56kPa26,72, the ABNP falls within range of reported values. 
The percent relaxation however for the ABNP tends to be higher than reported values for 
human NP due to how hydrated / swollen the ABNP scaffolds become through the 
decellularization process due to the increased porosity and GAG loss.  
 Through DMA testing the viscoelastic properties of the complex, storage, loss 
moduli and phase angle could be evaluated. Both ABNP and fresh bovine NPs were 
subjected to this unconfined DMA testing and compared to native human NP. The values 
for both the complex modulus and phase angle fall within the lower to mid range of 
human NP reported values, 7-21kPa and 23-31˚ respectively, over the frequencies tested. 
7,9 Therefore, with this data and the biochemical data it is possible that the ABNP can 
become a mechanically efficient replacement scaffold that would be aptly able to mimic 
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the native human NP at physiologically low strains long enough for cells to remodel and 
heal the degenerated IVD. 
 
4.5 In vitro Cell Studies  
 In conjunction with a decellularized scaffold, a NP tissue replacement would also 
require the use of cell sources that are capable to regenerate the NP ECM. Cells are 
needed to aid in tissue regeneration since they have been shown to aid in the remodeling 
and improvement of both biochemical and viscoelastic properties of the tissue.69,73–78 The 
use of autologous NP cells is not feasible for several reasons including, obtaining low 
yields of cells from harvest and damaging the disc causing more degeneration. 
Furthermore, NP cells harvested from degenerated discs exhibit altered phenotypes with 
reduced capacity for matrix synthesis and therefor should not be considered as a cell 
source.79 Stem cells are commonly used as an alternative source of healthy cells for tissue 
engineering applications. The use of human amniotic mesenchymal stem cells (hAMSCs) 
were chosen due to their high availably, as compared to bone marrow and adipose 
derived stem cells, and multipotent charecteristics.73,76,80 Furthermore, literature suggests 
biomimetic NP scaffolds may promote stem cell differentiation in the absence of 
exogenous cues.51,52  
 
4.6 In vitro Cell Injection Studies 
 Prior to this study we were able to demonstrate greater than 95% stem cell 
viability when seeding on the surface of the ABNP illustrating it’s cytocompatibility, 
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however cell penetration was not observed over the 14-day period. Therefore, we injected 
hAMSCs via a 28G syringe into the center of the ABNP scaffolds. Additionally a group 
of ABNP scaffolds were cross-linked using EDC/NHS fixation in order to cross-link 
GAGs to the collagen as a way to prevent scaffold destruction when implanted into a	destructive	environment	as	is	commonly	observed	in	the	degenerating	IVD.16,17,81–83 
From initial studies it is observable that cells were able to survive within the center of 
both the scaffolds however, viability was significantly higher in non-crosslinked 
scaffolds. This could be due to scaffolds not thoroughly being rinsed of crosslinking 
solution and will need to	be	optimized	in	future	studies	as	well	as	assessing	the	effect	of	crosslinking	on	mechanical	properties	of	cell	seeded	and	non-seeded	scaffolds.	
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CHAPTER FIVE 
CONCLUSIONS & RECOMMENDATIONS FOR FUTURE STUDIES 
5.1 Conclusion: 
 
Over the past decade, numerous advances in IDD treatments have been made in 
order to understand and address the causes of degeneration instead of treating the 
symptoms. However, current research has unable to create a scaffold that mimics both the 
biochemical and mechanical properties of NP. Groups have therefore been using 
decellularization to retain the native ECM and then seed cells onto these scaffolds to 
improve the native properties with limited success. Current problems with this technique 
are being able to maintain enough native ECM while also removing as much xenogeneic 
properties as possible.43,53,69 Results from the studies carried out within this publication 
have demonstrated the ability to fully decellularize the bovine NP. Our results suggest 
that an optimal decellularization procedure utilizes a combination of both physical and 
chemical methods. With this method it was possible to preserve the native NP ECM 
while also removing any significant xenogeneic material. Biochemical components and 
viscoelastic properties of the ABNP scaffold alone were similar to values of native 
human NP. Additionally the ABNP scaffold demonstrated excellent cytocompatibility 
with human stem cells further confirming its utility as a scaffold material for human NP 
tissue engineering.  
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5.2 Recommendations for Future Work 
The next logical step for future studies would be to both optimize and 
characterize, both biochemically and mechanically, the EDC: NHS cross-linked ABNP 
scaffolds as well as characterize both the stem cell seeded ABNP and cross-linked ABNP 
scaffolds. Following mechanical testing analysis, investigators will be able to determine 
how the crosslinking affects the mechanical properties of the cross-linked ABNP 
scaffolds. Stem cell characterization, in order to observe any differentiation into NP-like 
or notochordal-like cells, would aid investigators to better understand both the effects of a 
decellularized scaffold on cells as well as how well the scaffolds are able to provide cue 
for differentiation on stem cells. Additionally, a study utilizing factors associated with 
IDD to perform an accelerated degeneration model to observe how well both the ABNP 
and cross-linked ABNP scaffolds last in a degenerated environment. Further 
investigations, after additional scaffold characterization, would be to perform a large 
animal model to observe how scaffolds perform in vivo. The use of an animal with a large 
disc space and mechanically similar properties would be ideal in order to better observe 
clinically relevant results. 
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